Evidence map›Paper›PMID 32948925›Full record

ArticleInternational journal of clinical oncology2021

Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.

Yoshiaki Yamamoto, Junji Yatsuda, Mototsugu Shimokawa, Nakanori Fuji, Akihiko Aoki, Shigeru Sakano, Mitsutaka Yamamoto, Akinobu Suga, Yasuhide Tei, Satoru Yoshihiro and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 6 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 6 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Tumor-associated neutrophils suppress CD8British journal of cancer · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Yoshiaki YamamotoDepartment of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan.
Junji YatsudaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Nakanori FujiDepartment of Urology and Nephrology, Tokuyama Central Hospital, Shunan, Japan.
Akihiko AokiDepartment of Urology, Masuda Red Cross Hospital, Masuda, Japan.
Shigeru SakanoDepartment of Urology, Kokura Memorial Hospital, Kitakyusyu, Japan.
Mitsutaka YamamotoDepartment of Urology, Yamaguchi Grand Medical Center, Hofu, Japan.
Akinobu SugaDepartment of Urology, Yamaguchi Red Cross Hospital, Yamaguchi, Japan.
Yasuhide TeiDepartment of Urology, Kanmon Medical Center, 1-1-1, Shimonoseki, Japan.
Satoru YoshihiroDepartment of Urology, Shimonoseki City Hospital, Shimonoseki, Japan.
Seiji KitaharaDepartment of Urology, Sanyo-Onoda Municipal Hospital, Sanyo-Onoda, Japan.
Kazuhiro NagaoDepartment of Urology, Shuto General Hospital, Yanai, Japan.
Kimio TakaiDepartment of Urology, Saiseikai Shimonoseki General Hospital, Shimonoseki, Japan.
Yoriaki KamiryoDepartment of Urology, Shimonoseki Saiseikai Toyoura Hospital, Shimonoseki, Japan.
Jumpei AkaoDepartment of Urology, Ogori Daiichi General Hospital, Yamaguchi, Japan.
Shiro YamaguchiDepartment of Urology, Shimonoseki Medical Center, Shimonoseki, Japan.
Kazuo ObaDepartment of Urology, Saiseikai Yamaguchi General Hospital, Yamaguchi, Japan.
Tomoyuki ShimabukuroDepartment of Urology, Ube-kohsan Central Hospital Corp, Ube, Japan.
Hiroaki MatsumotoDepartment of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan.
Tomomi KambaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Hideyasu MatsuyamaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi, 755-8505, Japan. hidde@yamaguchi-u.ac.jp.ORCID http://orcid.org/0000-0001-5607-7769
Yamaguchi University · JPShimonoseki City Hospital · JPKumamoto University · JPSaiseikai Shimonoseki General Hospital · JPKokura Memorial Hospital · JPOgori Daiichi General Hospital · JPSanyo-Onoda City University · JPShuto General Hospital · JPTokuyama (Japan) · JPTsuda University · JPYamaguchi Prefecture Central Hospital · JPYamaguchi Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPembrolizumab is effective in a limited number of patients with advanced urothelial carcinoma (UC). Therefore, we evaluated the prognostic value of clinical biomarkers following pembrolizumab treatment in patients with advanced UC.

methodsWe retrospectively reviewed the medical records of 121 patients with platinum-refractory advanced UC who received pembrolizumab. Inflammation-based prognostic scores before and 6 weeks after the treatment were recorded. The categorical variables influencing overall survival (OS) and objective response rate (ORR) were analyzed.

resultsMultivariate analyses showed that pretreatment Eastern Cooperative Oncology Group (ECOG) performance score (PS), presence of only lymph node metastasis (only LN mets), C-reactive protein (CRP), and neutrophil/lymphocyte ratio (NLR) were independent prognostic factors for OS (P = 0.0077; RR = 2.42, P = 0.0049; RR = 0.36, P = 0.0047; RR = 2.53, and P = 0.0079; RR = 2.33, respectively). The pretreatment risk stratification using ECOG PS, only LN mets, CRP, and NLR was used for estimating the OS (P < 0.0001) and ORR (P < 0.0001). Furthermore, changes in NLR in response to pembrolizumab were significantly associated with the OS (P = 0.0002) and ORR (P = 0.0023). This change was also significantly correlated with OS even in the high-risk group stratified by this pretreatment risk stratification (P = 0.0069).

conclusionsThis pretreatment risk stratification may be used for estimating the OS and ORR of patients with advanced UC treated with pembrolizumab. If changes in NLR in response to pembrolizumab treatment improve, pembrolizumab should be continued.

Indexed as

LymphocytesNeutrophilsAntibodies, Monoclonal, HumanizedHumansPrognosisRetrospective StudiesRisk AssessmentAntibodies, Monoclonal, HumanizedpembrolizumabGlasgow prognostic scoreInflammation-based prognostic scoresNeutrophil/lymphocyte ratioPembrolizumabUrothelial carcinoma

Identifiers

PMID32948925
OpenAlexW3087616846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.